# Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

> **NCT04842370** · PHASE1 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** PHI-101

## Key facts

- **NCT ID:** NCT04842370
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-08
- **Primary completion:** 2022-05-21
- **Final completion:** 2022-05-21
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2021-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842370, "Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04842370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*